c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-24. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
=== Iberia === Vocabvlario da Lingoa de Iapam, a Japanese-Portuguese dictionary, was compiled and published in 1603 by Jesuit priests in Nagasaki. It contains short but clear definitions for about 20 words related to soyfoods—the first in any European language. The Luso-Hispanic traders were familiar with soybeans and soybean product through their trade with Far East since at least the 17th century. However, it was not until the late 19th century that the first attempt to cultivate soybeans in the Iberian peninsula was undertaken. In 1880, the soybean was first cultivated in Portugal in the Botanical Gardens at Coimbra (Crespi 1935). In about 1910 in Spain the first attempts at Soybean cultivation were made by the Count of San Bernardo, who cultivated soybeans on his estates at Almillo (in southwest Spain) about 48 miles east-northeast of Seville.
Biography at the Biographical Directory of the United States Congress Financial information (federal office) at the Federal Election Commission Legislation sponsored at the Library of Congress Profile at Vote Smart Campaign contributions at OpenSecrets.org Follow the Money – John Kennedy 2007 2005 2003 1999 Louisiana Treasurer campaign contributions
The M242 Bushmaster chain gun is a 25 mm (25×137mm) single-barrel chain-driven autocannon. It is used extensively by the U.S. military, such as in the Bradley fighting vehicle, as well as by other NATO members and some other nations in ground combat vehicles and various watercraft. Hughes Helicopters in Culver City, California, was the original designer and manufacturer. As of 2019, Northrop Grumman Innovation Systems produces the gun. It is an externally-powered, chain-driven, single-barrel weapon that may be fired in semi-automatic, burst, or automatic modes. It is fed by a metallic link belt and has dual-feed capability. The term chain gun derives from the use of a roller chain that drives the bolt back and forth. The gun can destroy lightly armored vehicles and aerial targets such as helicopters and other slow-flying aircraft. It can also apply suppression fire against exposed troops, dug-in positions, and occupied built-up areas. The standard rate of fire is 200 rounds per minute. The weapon has an effective range of 2,000 metres (6,600 ft), depending on the type of ammunition used. With over 11,000 units sold worldwide, it is one of the most successful modern autocannons.
Cardiac muscle is involuntary, striated muscle that is found in the walls and the histological foundation of the heart, specifically the myocardium. The cardiac muscle cells, (also called cardiomyocytes or myocardiocytes), predominantly contain only one nucleus, although populations with two to four nuclei do exist. The myocardium is the muscle tissue of the heart and forms a thick middle layer between the outer epicardium layer and the inner endocardium layer. Coordinated contractions of cardiac muscle cells in the heart propel blood out of the atria and ventricles to the blood vessels of the left/body/systemic and right/lungs/pulmonary circulatory systems. This complex mechanism illustrates systole of the heart. Cardiac muscle cells, unlike most other tissues in the body, rely on an available blood and electrical supply to deliver oxygen and nutrients and to remove waste products such as carbon dioxide. The coronary arteries help fulfill this function.
(ARP) publishers of the bodybuilding magazine Muscular Development and several other magazines. David Blechman retired in 1996, and passed the title of CEO to his son Ross, while the other sons were installed as corporate officers. He died on July 7, 2000. In 2001 Twinlab sold ARP to Steve Blechman who then resigned from Twinlab. After slumping sales in 2002, the company filed a voluntary petition for Chapter 11 reorganization with the U.S. Bankruptcy Court for the Southern District of New York in September 2003. In 2004, Twinlab Corp., Twin Laboratories Inc. and Twin Laboratories (UK) Ltd. were purchased for $65 million by IdeaSphere Inc. Ideasphere also known as ISI brands, and which also operated as Twinlab, went on to acquire other dietary supplement brands such as Metabolife, Nature's Herbs, Alvita Teas, and a publisher, Rebus LLC. In January 2014 Twinlab's CEO Tom Tolworthy announced that he would partner with Capstone Financial Group to raise $130M to conduct a management buyout of Twinlab and make other acquisitions, via an entity called Twinlab Consolidation Corporation. The transaction was completed in August 2014. In July 2018, Anthony Zolezzi, founder of Bubba Gump Shrimp Company and Pet Promise Natural Dog Food was named CEO of Twinlab, after being appointed to the Board of Directors the previous May.
Sources: en.wikipedia.org
Deadlift – 400 kg (882 lb) (2005 Pojedynek Gigantów) Keg drop Deadlift – 295–350 kg (650–771 lb) x 6 lifts in 33.89 seconds (2005 World's Strongest Man) Keg drop Squat – 265–340 kg (584–750 lb) x 7 reps in 21.28 seconds (2007 World's Strongest Man - Group 4) Keg drop Squat – 260–360 kg (573–794 lb) x 7 reps in 27.53 seconds (2005 World's Strongest Man) (former world record) Log lift – 172 kg (379 lb) (2005 Met-Rx Grand Prix) Log lift (for reps) – 130 kg (287 lb) x 14 reps (2006 Moscow Grand Prix) Axle press (for reps) – 140 kg (309 lb) x 11 reps (2006 WSMC Poland) (World Record) Apollon wheel press – 166 kg (366 lb) x 4 reps (2004 Arnold Strongman Classic) Viking press – 150 kg (331 lb) x 12 reps (2007 Mohegan Sun Grand Prix) Kettlebell press – 80 kg (176 lb) x 8 reps (2009 Globe's Strongest Man) Atlas Stones – 5 stones weighing 115–155 kg (254–342 lb) on tall platforms in 21.09 seconds (2006 Strongman Super Series Moscow Grand Prix) (World Record) Ding carry – 160 kg (353 lb) for 90 metres (2005 World's Strongest Man) (World Record) Asia Stone / shield carry – 175 kg (386 lb) for 127.4 metres (2002 World's Strongest Man) (World Record) Africa Stone carry – 175 kg (386 lb) for 110 metres (2000 World's Strongest Man - Group 5) (World Record) Block carry – 180 kg (397 lb) for 80 metre course in 41.32 seconds (2002 Europe's Strongest Man) (World Record) Fridge carry (super yoke) – 410 kg (904 lb) for 20 metres in 15.29 seconds (2005 World's Strongest Man) Timber carry – 392 kg (864 lb) (40' ramp) in 22.93 seconds (Raw grip) (2006 Arnold Strongman Classic) Wheelbarrow carry (no straps) – 300 kg (661 lb) (25m course) in 15.50 seconds (2003 IFSA Finland Grand Prix) (World Record) Farmer's walk (no straps) – 150 kg (331 lb) per each hand for 60m course in 19.90 seconds (2006 Strongman Super Series Poland Grand Prix) (World Record) Farmer's walk (no straps) – 137.5 kg (303 lb) per each hand for 70m course in 22.48 seconds (2003 Strongman Super Series Finland Grand Prix) (World Record) Super Yoke – 360 kg (794 lb) for 20 meters in 7.66 seconds (2006 World Strongman Cup Federation, Poland) (World Record) Medicine Ball Toss – 23 kg (51 lb) for 4.88 meters (2004 Arnold Strongman Classic) Power Stairs – (225 kg (496 lb) total of 14 steps) – 40.94 seconds (2008 World's Strongest Man) (World Record) Power Stairs – (230 kg (507 lb) total of 23 shallow steps) – 26.33 seconds (2006 World's Strongest Man) (World Record) Power Stairs – (200 kg (441 lb), 230 kg (507 lb) & 250 kg (551 lb) total of 15 high steps) – 31.22 seconds (2004 Europe's Strongest Man) (World Record) Power Stairs – (225 kg (496 lb), 250 kg (551 lb) & 275 kg (606 lb) total of 15 steps) – 28.56 seconds (2005 Nautilus Grand Prix) (World Record) Tyre Flip – 380 kg (838 lb) Tyre x 8 flips - 20.81 seconds (2004 Holland Champions Trophy) and 400 kg (882 lb) Tyre x 8 flips - 22.87 seconds (2006 Moscow Grand Prix) (former world records) Flip & drag – 400 kg (882 lb) tyre x 4 flips and 300 kg (661 lb) anchor & chain drag for 30 meters – 39.01 seconds (2002 World's Strongest Man) (world record) Conan's wheel (Basque circle) – 360 kg (794 lb) 765° rotation (2006 World Strongman Cup Russia) (World Record) Conan's wheel (Basque circle) – 317.5 kg (700 lb) 1,203° rotation (2003 Strongman Super Series Holland Grand Prix) (World Record) Conan's wheel (Basque circle) – 300 kg (661 lb) 1,440° rotation (2002 World's Strongest Man - Group 5) (former world record) Train pull – 16,000 kg (35,274 lb) for 25 meter course in 30.78 seconds (2003 World's Strongest Man) (World Record) Truck pull – 24,000 kg (52,911 lb) for 20 meter course in 26.05 seconds (2003 IFSA Strongman World Record Breakers) (World Record) Plane pull – 40,000 kg (88,185 lb) for 25 meter course in 36.67 seconds (2008 World's Strongest Man) (World Record) During training: (Self-claims)
Until the 1960s various manufacturers offered alleged wrinkle creams for external use (Hormocenta of Hormocenta Cosmetic Böttger GmbH, or Placentubex C of Merz Pharmaceuticals) containing human fat from placentas collected from midwives and obstetric departments for industrial purposes. The use of human placentas was terminated in favour of animal products. In 2009, a group of Peruvian gangsters, nicknamed "pishtacos" by the police, was accused of having manufactured and marketed human fat. However, the Peruvian Ministry of the Interior later described these allegations as a hoax. In the 2010s, MTF Biologics started providing Renuva (human cadaver fat) in syringes of up to 3 cubic centimetres (0.18 cu in). In 2024, Tiger Aesthetics marketed alloClae in syringes of up to 22 cubic centimetres (1.3 cu in). These preparations are being used as cosmetic filler. The demand has risen since the popularization of GLP-1 drugs has left thinner patients that feel that they lost fat in places that do not look good. Doctors say that customers are not concerned by the origin of the fat. Donors may have not been clear about the commercial use of their remains. In 2024, the New York State Health Department have denied a license to alloClae over doubts about the compliance with tissue donation laws. There can be complications with cadaver fat injections. If the fat does not vascularize, it may necrose, as in fat grafting from the patient's own body, but there are no studies comparing both methods. Cultural critic Arabelle Sicardi have compared alloClae to 2024 film The Substance.
10 January – British Post Office scandal: Prime Minister Rishi Sunak announces that emergency legislation would be brought through Parliament to "swiftly exonerate and compensate victims" of the Post Office scandal in England and Wales. First Minister of Scotland Humza Yousaf confirms those in Scotland convicted because of the scandal would also be cleared, and that he would work with the UK government to bring this about. 11 January – The Liberal Democrats ask Ofcom to investigate GB News over alleged bias in its coverage of the Post Office scandal, including what the party's deputy leader, Daisy Cooper, describes as "a fictitious monologue" Nigel Farage delivered about Sir Ed Davey, which she says contained "a number of factual inaccuracies". First Minister of Scotland Humza Yousaf confirms that the Scottish Government would "in essence replicate" the law in England and Wales banning unlicensed ownership of American XL bully dogs. Sunak authorises joint UK–US air strikes against Houthi rebels following attacks against cargo shipping targets in the Red Sea. 12 January – The Liberal Democrats, Scottish National Party and Plaid Cymru call for a recall of parliament to enable a vote on RAF involvement in the air strikes against Houthi rebels in Yemen, since Parliament had already risen for the weekend when Sunak authorised the UK's participation. Sunak authorises talks between the Labour Party and the civil service ahead of a general election later in the year to ensure a smooth transition if Labour becomes the party of government.
PGA is used for stabilizing the δ phase of plutonium, avoiding the α-phase and α–δ related issues. Its main use is in pits of implosion bombs. Plutonium–aluminium is an alternative to PGA. It was the original element considered for δ phase stabilization, but its tendency to react with the alpha particles and release neutrons reduces its usability for nuclear weapons. Plutonium–aluminium alloy can be also used as a component of nuclear fuel. Plutonium–gallium–cobalt alloy (PuCoGa5) is an unconventional superconductor, showing superconductivity below 18.5 K, an order of magnitude higher than the highest between heavy fermion systems, and has large critical current. Plutonium–zirconium alloy can be used as nuclear fuel. Plutonium–cerium and plutonium–cerium–cobalt alloys are used as nuclear fuels. Plutonium–uranium, with about 15–30 mol.% plutonium, can be used as a nuclear fuel for fast breeder reactors. Its pyrophoric nature and high susceptibility to corrosion to the point of self-igniting or disintegrating after exposure to air require alloying with other components. Addition of aluminium, carbon or copper does not improve disintegration rates markedly, zirconium and iron alloys have better corrosion resistance but they disintegrate in several months in air as well. Addition of titanium and/or zirconium significantly increases the melting point of the alloy. Plutonium–uranium–titanium and plutonium–uranium–zirconium were investigated for use as nuclear fuels.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.